Last reviewed · How we verify

NCT05354336

A Phase I Clinical Study on SHR6390 in Healthy Chinese Volunteers

Completed Phase 1 Last updated 5 May 2022
What this trial tests

Phase 1 trial testing SHR6390(100mg) in Healthy Volunteers in 36 participants. Completed in 24 August 2019.

Timeline
13 June 2019
Primary endpoint
24 August 2019
24 August 2019

Quick facts

Lead sponsorThe Affiliated Hospital of Qingdao University
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment36
Start date13 June 2019
Primary completion24 August 2019
Estimated completion24 August 2019
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

The Affiliated Hospital of Qingdao University

Who can join

Adults 18 to 45, any sex, with Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study was to evaluate the pharmacokinetics and safety of SHR6390 at doses of 100 mg, 125 mg, and 150 mg after process modification in Chinese healthy volunteers. A single oral dose of SHR6390 was given to each group, including 100 mg, 125mg and 150mg of SHR6390.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other The Affiliated Hospital of Qingdao University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05354336.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing